바이오시밀러 단클론항체 시장 분석 및 예측(-2035년) : 유형별, 제품별, 용도별, 기술별, 최종 사용자별, 프로세스별, 배포별, 기능별, 구성 요소별

Biosimilar Monoclonal Antibody Market is anticipated to expand from $10.7 billion in 2024 to $72 billion by 2034, growing at a CAGR of approximately 24.9%. The Biosimilar Monoclonal Antibody Market encompasses biologic medical products highly similar to already approved monoclonal antibodies, offering cost-effective alternatives without compromising efficacy or safety. This market is driven by patent expirations of original biologics, increasing chronic disease prevalence, and healthcare cost containment efforts. Regulatory frameworks and advancements in biotechnology are pivotal in shaping market dynamics, fostering competition, and facilitating access to life-saving therapies globally.

The Biosimilar Monoclonal Antibody Market is experiencing robust growth, propelled by the increasing demand for cost-effective therapeutic alternatives. The oncology segment leads in performance, driven by the prevalence of cancer and the need for affordable treatment options. Within oncology, biosimilars targeting breast cancer and colorectal cancer are particularly prominent due to high incidence rates and established treatment protocols. The autoimmune diseases segment follows closely, with biosimilars for rheumatoid arthritis and psoriasis gaining significant traction. These are supported by the rising prevalence of autoimmune conditions and the consequent need for long-term treatment solutions. The market's expansion is further bolstered by advancements in biotechnology, enhancing the efficacy and safety profiles of biosimilars. Strategic collaborations between pharmaceutical companies and healthcare providers are fostering greater market penetration. Regulatory support, alongside streamlined approval processes, is facilitating quicker market entry, thereby accelerating growth. The emphasis on reducing healthcare costs and improving patient access to biologic therapies remains a key market driver.

The biosimilar monoclonal antibody market is witnessing a dynamic shift in market share, driven by competitive pricing strategies and a surge in new product launches. Established players are leveraging cost-effective production techniques to enhance their competitive edge, while new entrants are disrupting the market with innovative therapies. The landscape is characterized by strategic collaborations and partnerships, which are pivotal in accelerating market penetration and adoption. This vibrant ecosystem is fostering a competitive environment that is reshaping pricing models and expanding access to these critical therapies. Competition benchmarking reveals that leading companies are investing heavily in R&D to maintain their market dominance. Regulatory influences play a crucial role, with stringent approval processes impacting market entry and expansion. The European Medicines Agency and the U.S. FDA are pivotal in shaping market dynamics through their rigorous regulatory frameworks. Market analysis indicates a trend towards increased biosimilar approvals, which is expected to drive market growth. This comprehensive study underscores the importance of strategic agility and regulatory compliance in navigating the biosimilar monoclonal antibody market.

Geographical Overview:

The biosimilar monoclonal antibody market is witnessing substantial growth across various regions, each exhibiting unique dynamics. North America remains at the forefront, driven by the increasing demand for cost-effective biologics and a favorable regulatory framework. The presence of major pharmaceutical companies and ongoing research initiatives further bolster the market's expansion. Europe follows closely, with strong governmental support and strategic partnerships enhancing the development and adoption of biosimilars. The region's emphasis on reducing healthcare costs also contributes to its market allure. In Asia Pacific, the market is expanding rapidly, driven by rising healthcare expenditures and an increasing prevalence of chronic diseases. Emerging economies such as China and India are becoming pivotal players, with significant investments in biosimilar research and development. Latin America and the Middle East & Africa are emerging markets with growing potential. Latin America is experiencing a surge in biosimilar approvals, while the Middle East & Africa are recognizing the role of biosimilars in improving healthcare accessibility and affordability.

Global tariffs and geopolitical tensions are significantly influencing the Biosimilar Monoclonal Antibody Market. In Japan and South Korea, reliance on imported biopharmaceutical ingredients is prompting investments in local production capabilities to mitigate tariff impacts. China's strategy focuses on bolstering domestic biosimilar development, reducing dependency on Western imports amidst trade tensions. Taiwan, with its robust pharmaceutical manufacturing, remains crucial yet geopolitically sensitive. The parent market is experiencing robust growth due to increasing demand for cost-effective biologics, projected to expand significantly by 2035 with advancements in biotechnology. Middle East conflicts, while not directly impacting biosimilars, affect global supply chains and energy prices, indirectly influencing production costs. The market's evolution will hinge on strategic regional collaborations and technological innovations to navigate these complexities.

Key Trends and Drivers:

The biosimilar monoclonal antibody market is experiencing robust growth due to increasing demand for cost-effective biologics and the expiration of patents for major biologic drugs. Key trends include the rising adoption of biosimilars in oncology and autoimmune diseases, driven by their efficacy and affordability. Regulatory bodies are increasingly supporting biosimilar approvals, streamlining pathways to encourage market entry and competition. This regulatory support is fostering innovation and investment in biosimilar development. Drivers of this market include the growing burden of chronic diseases and the need for affordable treatment options. Healthcare systems globally are under pressure to reduce costs, making biosimilars an attractive option. The increasing acceptance of biosimilars among healthcare professionals and patients is further propelling market growth. Opportunities lie in emerging markets where access to biologics has been limited, providing a significant potential for expansion. Moreover, advancements in manufacturing technologies are enhancing the production efficiency and quality of biosimilars, reducing time-to-market. Companies that can leverage these technological advancements and establish strategic partnerships are well-positioned to gain a competitive edge. As the market continues to evolve, there is a significant opportunity for growth in regions with supportive regulatory frameworks and high biologic drug consumption.

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Application
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Deployment
• 2.8 Key Market Highlights by Functionality
• 2.9 Key Market Highlights by Component

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Chimeric Antibodies
  • 4.1.2 Humanized Antibodies
  • 4.1.3 Fully Human Antibodies
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Infliximab
  • 4.2.2 Rituximab
  • 4.2.3 Trastuzumab
  • 4.2.4 Adalimumab
  • 4.2.5 Bevacizumab
  • 4.2.6 Etanercept
• 4.3 Market Size & Forecast by Application (2020-2035)
  • 4.3.1 Oncology
  • 4.3.2 Autoimmune Diseases
  • 4.3.3 Infectious Diseases
  • 4.3.4 Hematological Disorders
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Recombinant DNA Technology
  • 4.4.2 Hybridoma Technology
  • 4.4.3 Transgenic Mice Technology
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Biopharmaceutical Companies
  • 4.5.5 Contract Research Organizations
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Upstream Processing
  • 4.6.2 Downstream Processing
• 4.7 Market Size & Forecast by Deployment (2020-2035)
  • 4.7.1 In-house Manufacturing
  • 4.7.2 Contract Manufacturing
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Therapeutic
  • 4.8.2 Diagnostic
• 4.9 Market Size & Forecast by Component (2020-2035)
  • 4.9.1 Active Pharmaceutical Ingredients
  • 4.9.2 Formulations

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Application
    • 5.2.1.4 Technology
    • 5.2.1.5 End User
    • 5.2.1.6 Process
    • 5.2.1.7 Deployment
    • 5.2.1.8 Functionality
    • 5.2.1.9 Component
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Application
    • 5.2.2.4 Technology
    • 5.2.2.5 End User
    • 5.2.2.6 Process
    • 5.2.2.7 Deployment
    • 5.2.2.8 Functionality
    • 5.2.2.9 Component
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Application
    • 5.2.3.4 Technology
    • 5.2.3.5 End User
    • 5.2.3.6 Process
    • 5.2.3.7 Deployment
    • 5.2.3.8 Functionality
    • 5.2.3.9 Component
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Application
    • 5.3.1.4 Technology
    • 5.3.1.5 End User
    • 5.3.1.6 Process
    • 5.3.1.7 Deployment
    • 5.3.1.8 Functionality
    • 5.3.1.9 Component
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Application
    • 5.3.2.4 Technology
    • 5.3.2.5 End User
    • 5.3.2.6 Process
    • 5.3.2.7 Deployment
    • 5.3.2.8 Functionality
    • 5.3.2.9 Component
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Application
    • 5.3.3.4 Technology
    • 5.3.3.5 End User
    • 5.3.3.6 Process
    • 5.3.3.7 Deployment
    • 5.3.3.8 Functionality
    • 5.3.3.9 Component
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Application
    • 5.4.1.4 Technology
    • 5.4.1.5 End User
    • 5.4.1.6 Process
    • 5.4.1.7 Deployment
    • 5.4.1.8 Functionality
    • 5.4.1.9 Component
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Application
    • 5.4.2.4 Technology
    • 5.4.2.5 End User
    • 5.4.2.6 Process
    • 5.4.2.7 Deployment
    • 5.4.2.8 Functionality
    • 5.4.2.9 Component
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Application
    • 5.4.3.4 Technology
    • 5.4.3.5 End User
    • 5.4.3.6 Process
    • 5.4.3.7 Deployment
    • 5.4.3.8 Functionality
    • 5.4.3.9 Component
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Application
    • 5.4.4.4 Technology
    • 5.4.4.5 End User
    • 5.4.4.6 Process
    • 5.4.4.7 Deployment
    • 5.4.4.8 Functionality
    • 5.4.4.9 Component
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Application
    • 5.4.5.4 Technology
    • 5.4.5.5 End User
    • 5.4.5.6 Process
    • 5.4.5.7 Deployment
    • 5.4.5.8 Functionality
    • 5.4.5.9 Component
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Application
    • 5.4.6.4 Technology
    • 5.4.6.5 End User
    • 5.4.6.6 Process
    • 5.4.6.7 Deployment
    • 5.4.6.8 Functionality
    • 5.4.6.9 Component
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Application
    • 5.4.7.4 Technology
    • 5.4.7.5 End User
    • 5.4.7.6 Process
    • 5.4.7.7 Deployment
    • 5.4.7.8 Functionality
    • 5.4.7.9 Component
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Application
    • 5.5.1.4 Technology
    • 5.5.1.5 End User
    • 5.5.1.6 Process
    • 5.5.1.7 Deployment
    • 5.5.1.8 Functionality
    • 5.5.1.9 Component
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Application
    • 5.5.2.4 Technology
    • 5.5.2.5 End User
    • 5.5.2.6 Process
    • 5.5.2.7 Deployment
    • 5.5.2.8 Functionality
    • 5.5.2.9 Component
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Application
    • 5.5.3.4 Technology
    • 5.5.3.5 End User
    • 5.5.3.6 Process
    • 5.5.3.7 Deployment
    • 5.5.3.8 Functionality
    • 5.5.3.9 Component
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Application
    • 5.5.4.4 Technology
    • 5.5.4.5 End User
    • 5.5.4.6 Process
    • 5.5.4.7 Deployment
    • 5.5.4.8 Functionality
    • 5.5.4.9 Component
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Application
    • 5.5.5.4 Technology
    • 5.5.5.5 End User
    • 5.5.5.6 Process
    • 5.5.5.7 Deployment
    • 5.5.5.8 Functionality
    • 5.5.5.9 Component
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Application
    • 5.5.6.4 Technology
    • 5.5.6.5 End User
    • 5.5.6.6 Process
    • 5.5.6.7 Deployment
    • 5.5.6.8 Functionality
    • 5.5.6.9 Component
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Application
    • 5.6.1.4 Technology
    • 5.6.1.5 End User
    • 5.6.1.6 Process
    • 5.6.1.7 Deployment
    • 5.6.1.8 Functionality
    • 5.6.1.9 Component
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Application
    • 5.6.2.4 Technology
    • 5.6.2.5 End User
    • 5.6.2.6 Process
    • 5.6.2.7 Deployment
    • 5.6.2.8 Functionality
    • 5.6.2.9 Component
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Application
    • 5.6.3.4 Technology
    • 5.6.3.5 End User
    • 5.6.3.6 Process
    • 5.6.3.7 Deployment
    • 5.6.3.8 Functionality
    • 5.6.3.9 Component
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Application
    • 5.6.4.4 Technology
    • 5.6.4.5 End User
    • 5.6.4.6 Process
    • 5.6.4.7 Deployment
    • 5.6.4.8 Functionality
    • 5.6.4.9 Component
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Application
    • 5.6.5.4 Technology
    • 5.6.5.5 End User
    • 5.6.5.6 Process
    • 5.6.5.7 Deployment
    • 5.6.5.8 Functionality
    • 5.6.5.9 Component

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Coherus Bio Sciences
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Alvotech
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Samsung Bioepis
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Celltrion Healthcare
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Biocon Biologics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Amgen
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Mylan
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Sandoz
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Teva Pharmaceutical Industries
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Pfizer
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Fresenius Kabi
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Dr Reddy's Laboratories
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Stada Arzneimittel
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Shanghai Henlius Biotech
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Bio- Thera Solutions
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Intas Pharmaceuticals
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Apotex
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Hikma Pharmaceuticals
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Lupin
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Cadila Healthcare
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us